PALO ALTO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its quarterly conference call and webcast will be held on Monday, November 6, 2006 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company’s financial results for the third quarter and nine months ended September 30, 2006.
The conference call will be accessible via Telik’s website at www.telik.com or by telephone at 800-230-1059 or 612-332-0107. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 846690. The archive will be available from approximately 8:30 p.m. Eastern time on November 6 through November 13, 2006.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(R) (TLK286), a tumor-activated small molecule product candidate which is in four Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications, ofTelik, Inc., +1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com/
